HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Appendix Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Carnahan, R. M. Articles by Culp, K. R. Search for Related Content PubMed PubMed Citation Articles by Carnahan, R. M. Articles by Culp, K. R.

The Anticholinergic Drug Scale as a Measure of Drug-Related Anticholinergic Burden: Associations With Serum Anticholinergic Activity

From the University of Oklahoma College of Pharmacy, Department of Pharmacy: Clinical and Administrative Sciences, Tulsa, Oklahoma (Dr Carnahan); Laureate Psychiatric Research Center, Tulsa, Oklahoma (Dr Lund); Touro University—California College of Pharmacy, Vallejo, California (Dr Perry); the University of Iowa Roy J. and Lucille A. Carver College of Medicine, Department of Psychiatry, Iowa City, Iowa (Dr Perry); Rotman Research Institute, Baycrest Centre for Geriatric Care, University of Toronto, Toronto, Ontario, Canada (Dr Pollock); the University of Iowa College of Nursing, Iowa City, Iowa (Dr Culp).

Anticholinergic Drug Scale (ADS) scores were previously associated with serum anticholinergic activity (SAA) in a pilot study. To replicate these results, the association between ADS scores and SAA was determined using simple linear regression in subjects from a study of delirium in 201 long-term care facility residents who were not included in the pilot study. Simple and multiple linear regression models were then used to determine whether the ADS could be modified to more effectively predict SAA in all 297 subjects. In the replication analysis, ADS scores were significantly associated with SAA (R² = .0947, P < .0001). In the modification analysis, each model significantly predicted SAA, including ADS scores (R² = .0741, P < .0001). The modifications examined did not appear useful in optimizing the ADS. This study replicated findings on the association of the ADS with SAA. Future work will determine whether the ADS is clinically useful for preventing anticholinergic adverse effects.

Key Words: Anticholinergics • serum anticholinergic activity • Anticholinergic Drug Scale

Address for reprints: Ryan Carnahan, PharmD, the University of Oklahoma College of Pharmacy, 4502 E. 41st Street, Suite 2H19, Tulsa, Oklahoma 74315-2512; e-mail: ryan-carnahan{at}ouhsc.edu.

This article has been cited by other articles:

				J. L. Rudolph, M. J. Salow, M. C. Angelini, and R. E. McGlinchey The Anticholinergic Risk Scale and Anticholinergic Adverse Effects in Older Persons Arch Intern Med, March 10, 2008; 168(5): 508 - 513. [Abstract] [Full Text] [PDF]

				K. A. Swanson and R. M. Carnahan Dementia and Comorbidities: An Overview of Diagnosis and Management Journal of Pharmacy Practice, August 1, 2007; 20(4): 296 - 317. [Abstract] [PDF]